While FABP4 was identified as an attractive target to protect barrier injury resulting from tight junction degradation40, 42, 43, 44 and encouraging survival results have been reported in infection45, 46 and aging‐associated metabolic disorders,47 our results provide strong rationale for targeting FABP4 in the context of lung injury. The gene discussed is FABP4; the disease is metabolic disease.